1. Is RPG Life Sciences Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that RPG Life Sciences Ltd is a average quality company.
2. Is RPG Life Sciences Ltd undervalued or overvalued?
The key valuation ratios of RPG Life Sciences Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
3. Is RPG Life Sciences Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of RPG Life Sciences Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘ
Value Creation Index Colour Code Guide ⓘ
|ROCE % ⓘ||6.7%||6.3%||1.6%||8.2%||13.6%||8.3%||6.8%||17.9%||20.2%||21.9%||-|
|Value Creation Index ⓘ||-0.5||-0.6||-0.9||-0.4||-0.0||-0.4||-0.5||0.3||0.4||0.6||-|
Growth Parameters ⓘ
Growth Parameters Colour Code Guide ⓘ
|YoY Gr. Rt. %||-||6.3%||2.9%||15.3%||5.1%||17.1%||-4%||13.8%||3.6%||13.1%||-|
|Adj EPS ⓘ||2.2||4.2||0.3||6.7||12.8||8||6.3||19.6||24||30.8||36.5|
|YoY Gr. Rt. %||-||89.2%||-93.3%||2296.4%||90%||-37.1%||-21.7%||212.4%||22.2%||28.5%||-|
|BVPS (₹) ⓘ||46.1||76.1||75.7||80.8||88.9||93.6||97.1||106.8||130.9||154.7||168.1|
|Adj Net Profit ⓘ||3.7||7||0.5||11.1||21.1||13.3||10.4||32.5||39.7||51||60|
|Cash Flow from Ops. ⓘ||12.3||-5.6||-2||32.8||7.3||14.7||45.8||50.2||58.3||64.8||-|
|Debt/CF from Ops. ⓘ||5.1||-2.6||-16.9||0.7||6.1||3.7||0.8||0.2||0||0||-|
CAGR Colour Code Guide ⓘ
|9 Years||5 Years||3 Years||1 Years|
|Adj EPS ⓘ||34%||19.3%||69.9%||28.5%|
Key Financial Parameters ⓘ
Performance Ratio Colour Code Guide ⓘ
|Return on Equity % ⓘ||4.9||6.9||0.4||8.6||15||8.8||6.6||19.3||20.2||21.6||22.6|
|Op. Profit Mgn % ⓘ||7.1||4.8||3.5||8||9.8||10.8||10.5||16||18.2||19.8||19.7|
|Net Profit Mgn % ⓘ||1.7||3||0.2||4||7.2||3.9||3.2||8.6||10.2||11.6||12.5|
|Debt to Equity ⓘ||0.8||0.1||0.3||0.2||0.3||0.4||0.2||0.1||0||0||0|
|Working Cap Days ⓘ||146||154||150||137||123||126||136||115||118||105||157|
|Cash Conv. Cycle ⓘ||31||36||52||48||49||55||55||48||44||40||98|
Return on Equity has increased versus last 3 years average to 22.60%
Sales growth is growing at healthy rate in last 3 years 10.06%
Net Profit is growing at healthy rate in last 3 years 69.94%
Sales growth is good in last 4 quarters at 14.55%
No data to display
|TTM EPS (₹)||36.5||5|
|TTM Sales (₹ Cr.)||483||121|
|BVPS (₹.) ⓘ||168.1||0|
|Reserves (₹ Cr.) ⓘ||265||-|
|From the Market|
|52 Week Low / High (₹)||451.80 / 1012.45|
|All Time Low / High (₹)||17.10 / 1012.45|
|Market Cap (₹ Cr.)||1,477|
|Equity (₹ Cr.)||13.2|
|Face Value (₹)||8|
|Industry PE ⓘ||37.7|
RPG Life Sciences (RPGLS) is a pharmaceutical organization and was formerly known as Searle (India) Limited. It is a full spectrum world class, customer focussed, innovative pharmaceutical organisation. RPGLS started in 1968 as a joint venture with GD Searle, USA. In 1993, GD Searle withdrew from India and sold its holdings to the RPG Group. The companyâ€™s name was changed to RPG Life Sciences Ltd effective April 1, 1999.This company belongs to RPG group
RPGLS was in the business of pharmaceuticals and agrochemicals. It divested the agrochemicals business in the year 2001, as per the strategic decision to focus on pharmaceuticals, fermentation and biotechnology. It develops, manufactures and markets, for national and international markets, a broad range of branded formulations, generics and bulk drugs developed through fermentation and chemical synthesis routes. RPG Life Sciences has research and development facilities that conform to international standards. It has Biotech R&D, API R&D and Formulations R&D. Each of these areas have their respective manufacturing facilities RPGLS employs 750 people. It is a multi-location pharmaceutical manufacturing company with four locations. The manufacturing unit at Thane produces Active Pharmaceuticals Ingredients (also called as bulk drugs) and is ISO 9001 certified and has Therapeutic Goods Administration (TGA), Australia, and approval for three of its major products namely Diphenoxylate Hydrochloride, Haloperidol and Propanthelene Bromide.
The Formulation Plant at Ankleshwar GIDC is ISO 9002 and ISO14001 certified and manufactures pharmaceuticals formulations for domestic as well as for exports. The site also has MHRA (Medicines and Healthcare products Regulatory Agency, UK) approved plant for catering to its global generic business. The second plant at Ankleshwar makes API through the fermentation route to cater to the biotech business.
RPGLS is present in the domestic as well as the international markets. It exports its products primarily to Europe, Latin America, Africa, Australia, CIS Nations and South East Asia.
Major Activities of the Company:
It is represented in over thirty countries through strategic partnerships and joint ventures.